U.S. patent application number 10/279061 was filed with the patent office on 2003-09-11 for process for the production of alpha-human atrial natriuretic polypeptide.
This patent application is currently assigned to Fujisawa Pharmaceutical Co., Ltd.. Invention is credited to Ishii, Yoshinori, Niwa, Mineo, Saito, Yoshimasa, Ueda, Ikuo, Yamada, Hisashi.
Application Number | 20030170811 10/279061 |
Document ID | / |
Family ID | 26289399 |
Filed Date | 2003-09-11 |
United States Patent
Application |
20030170811 |
Kind Code |
A1 |
Ueda, Ikuo ; et al. |
September 11, 2003 |
Process for the production of alpha-human atrial natriuretic
polypeptide
Abstract
The present invention relates to a process for the production of
.alpha.-human atrial natriuretic polypeptide by recombinant DNA
technology.
Inventors: |
Ueda, Ikuo; (Toyonaka,
JP) ; Niwa, Mineo; (Mukou, JP) ; Saito,
Yoshimasa; (Osaka, JP) ; Yamada, Hisashi;
(Kawanishi, JP) ; Ishii, Yoshinori; (Suita,
JP) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
Fujisawa Pharmaceutical Co.,
Ltd.
Osaka
JP
|
Family ID: |
26289399 |
Appl. No.: |
10/279061 |
Filed: |
October 24, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10279061 |
Oct 24, 2002 |
|
|
|
09531488 |
Mar 20, 2000 |
|
|
|
09531488 |
Mar 20, 2000 |
|
|
|
08638941 |
Apr 25, 1996 |
|
|
|
08638941 |
Apr 25, 1996 |
|
|
|
08370356 |
Jan 9, 1995 |
|
|
|
6403336 |
|
|
|
|
08370356 |
Jan 9, 1995 |
|
|
|
08073043 |
Jun 8, 1993 |
|
|
|
08073043 |
Jun 8, 1993 |
|
|
|
07385952 |
Jul 28, 1989 |
|
|
|
07385952 |
Jul 28, 1989 |
|
|
|
06875880 |
Jun 18, 1986 |
|
|
|
Current U.S.
Class: |
435/69.1 ;
435/252.33; 435/320.1; 530/350 |
Current CPC
Class: |
C07K 2319/50 20130101;
C07K 2319/75 20130101; C07K 14/58 20130101; A61P 7/10 20180101;
C12N 15/70 20130101; C07K 2319/32 20130101; A61P 9/12 20180101;
C07K 2319/00 20130101 |
Class at
Publication: |
435/69.1 ;
435/320.1; 435/252.33; 530/350 |
International
Class: |
C12P 021/02; C12N
001/21; C07K 014/47; C12N 015/74 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 20, 1985 |
GB |
8515686 |
Jan 14, 1986 |
GB |
8600754 |
Claims
We claim:
1. A process for the production of .alpha.-hANP by (1) culturing a
microorganism transformed with an expression vector comprising a
synthetic gene encoding an amino acid sequence of a protective
peptide-fused .alpha.-hANP in a nutrient medium, (2) recovering the
protective peptide-fused .alpha.-hANP from the cultured broth and
(3) removing the protective peptide portion of the protective
peptide-fused .alpha.-hANP.
2. A process for the production of .alpha.-hANP of claim 1, in
which the microorganism is bacteria.
3. A process for the production of .alpha.-hANP of claim 2, in
which the bacteria is a strain belonging to the genus
Escherichia.
4. A process for the production of .alpha.-hANP of claim 3, in
which the strain is Escherichia coli.
5. A process for the production of .alpha.-hANP of claim 1, in
which .alpha.-hANP gene portion of the synthetic gene is
represented by the following DNA sequence:
6 Coding: 5'-TCT CTG CGT AGA TCC TCT TGC TTT GGT Noncoding: 3'-AGA
GAC GCA TCT AGG AGA ACG AAA CCA GGC CGT ATG GAC CGC ATC GGT GCT CAG
TCC GGT CTG CCG GCA TAC CTG GCG TAG CCA CGA GTC AGG CCA GAC GGC TGT
AAC TCT TTC CGT TAC-3' CCG ACA TTG AGA AAG GCA ATG-5'
6. A process for the production of .alpha.-hANP of claim 1, in
which the protective peptide-fused .alpha.-hANP has the amino acid
sequence represented in FIG. 17.
7. A process for the production of .alpha.-hANP of claim 1, the
protectice peptide portion of protective peptide-fused .alpha.-hANP
is removed in the presence of API.
8. A chemically synthsized gene encoding amino acid sequence of
.alpha.-hANP:
H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-I-
le-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH
9. The chemically synthsized gene of claim 8, which is represented
by the following DNA sequence:
7 Coding: 5'-TCT CTG CGT AGA TCC TCT TGC TTT GGT Noncoding: 3'-AGA
GAC GCA TCT AGG AGA ACG AAA CCA GGC CGT ATG GAC CGC ATC GGT GCT CAG
TCC GGT CTG CCG GCA TAC CTG GCG TAG CCA CGA GTC AGG CCA GAC GGC TGT
AAC TCT TTC CGT TAC-3' CCG ACA TTG AGA AAG GCA ATG-5'
10. A chemically synthesized protective peptide gene having DNA
sequence encoding lysine as C-terminal of the protective
peptide.
11. The chemically synthesized protective peptide gene of claim 10,
which is represented by the DNA sequence of FIG. 4.
12. A recombinant vector comprising chemically synthesized
.alpha.-hANP gene.
13. A recombinant vector of claim 13, in which the .alpha.-hANP
gene is represented by the following DNA sequence:
8 Coding: 5'-TCT CTG CGT AGA TCC TCT TGC TTT GGT Noncoding: 3'-AGA
GAC GCA TCT AGG AGA ACG AAA CCA GGC CGT ATG GAC CGC ATC GGT GCT CAG
TCC GGT CTG CCG GCA TAC CTG GCG TAG CCA CGA GTC AGG CCA GAC GGC TGT
AAC TCT TTC CGT TAC-3' CCG ACA TTG AGA AAG GCA ATG-5'
14. A recombinant vector comprising chemically synthesized gene
represented by the DNA sequence of FIG. 17.
15. A recombinant vector comprising chemically synthesized gene
represented by the DNA sequence of FIG. 4.
16. A transformant comprising expression vector of chemically
synthesized .alpha.-hANP gene.
17. A transformant of claim 16, in which the .alpha.-hANP gene is
presented by the following DNA sequence:
9 Coding: 5'-TCT CTG CGT AGA TCC TCT TGC TTT GGT Noncoding: 3'-AGA
GAC GCA TCT AGG AGA ACG AAA CCA GGC CGT ATG GAC CGC ATC GGT GCT CAG
TCC GGT CTG CCG GCA TAC CTG GCG TAG CCA CGA GTC AGG CCA GAC GGC TGT
AAC TCT TTC CGT TAC-3' CCG ACA TTG AGA AAG GCA ATG-5'
18. A cleaving method of the fused-protein composed of a peptides
having a lysine between a protective peptide and a targent peptide
in the presence of API.
19. Synthetic trp promoter III represented by the DNA sequence of
FIG. 3.
Description
[0001] This invention relates to a new process for the production
of .alpha.-human atrial natriuretic polypeptide (hereinafter
referred to as the abbreviation ".alpha.-hANP") by recombinant DNA
technology. More particularly, it relates to a new process for the
production of .alpha.-hANP by recombinant DNA technology, to
chemically synthesized genes for .alpha.-hANP and protective
peptide-fused .alpha.-hANP and to a corresponding recombinant
vector and transformant comprising the same.
[0002] The .alpha.-hANP is a known polypeptide having a diuretic,
natriuretic, vasorelaxant and antihypertensive activities.
Therefore, it may be useful in clinical treatment of hypertension
as antihypertensive diuretic agent and has the following structure:
1
[0003] (Cf. Biochemical and Biophysical Research Communications
Vol.118, page 131 (1984)).
[0004] The inventors of this invention have newly created a process
for the production of .alpha.-hANP by recombinant DNA technique
using an expression vector comprising a synthetic gene encoding the
amino acid sequence (I) of .alpha.-hANP. According to this process,
.alpha.-hANP can be obtained in high yield.
[0005] This invention provide a process for the production of
.alpha.-hANP by (1) culturing a microorganism transformed with an
expression vector comprising a synthetic gene encoding an amino
acid sequence of a protective peptide-fused .alpha.-hANP in a
nutrient medium, (2) recovering the protective peptide-fused
.alpha.-hANP from the cultured broth and (3) removing the
protective peptide part of the protective peptide-fused
.alpha.-hANP.
[0006] In the above process, particulars of which are explained in
more detail as follows.
[0007] The microorganism is a host cell and may include bacteria,
fungi, cultured human and animal cells and cultured plant cells.
Preferred examples of the microorganism may include bacteria
especially a strain belonging to the genus Escherichia (e.g. E.
coli HB101 (ATCC 33694), E. coli 294 (ATCC 31446), E. coli .chi.
1776 (ATCC 31537), etc).
[0008] The expression vector is usually composed of DNA having at
least a promoter-operater region, initiation codon, synthetic
protective peptide gene, synthetic .alpha.-hANP gene, termination
codon(s) and replicatable unit.
[0009] The promoter-operater region comprises promoter, operater
and Shine-Dalgarno (SD) sequence (e.g. AAGG, etc.). The distance
between SD sequence and intiation codon is preferably 8-12 b. p.
and in the most preferable case as shown in the working Examples
mentioned below, the distance between SD sequence and initiation
codon (ATG) is 11 b.p. Examples of the promoter-operater region may
include conventionally employed promoter-operater region (e.g.
lactose-operon, PL-promoter, trp-promoter, etc.) as well as
synthetic promoter-operater region. Preferred examples of the
promoter-operater region are synthetic trp promoter I, II and III
which were newly synthesized by the inventors of this invention and
DNA sequences thereof are shown in FIGS. 1, 2 and 3, respectively.
In the process, there may be used 1-3 consecutive promoter-operater
region(s) per expression vector.
[0010] Preferred initiation codon may include methionine codon
(ATG).
[0011] The protective peptide gene may include DNA sequence
corresponding to any of peptide or protein which is capable of
forming a fused protein with .alpha.-hANP and inhibiting undesired
degradation of the fused protein in the host cell or the cultured
broth. One of preferred examples is "peptide Cd gene" linked to "LH
protein gene" (hereinafter "the peptide Cd gene linked to LH
protein gene" is referred to as "peptide CLa gene"), DNA sequence
of which is shown in FIG. 4.
[0012] The DNA sequence of .alpha.-hANP gene is designed from the
amino acid sequence of .alpha.-hANP, subjected to a number of
specific non-obvious criteria. Preferred example of DNA sequence of
.alpha.-hANP gene is shown in FIG. 5. In the working Examples as
mentioned below, between the .alpha.-hANP gene and the protective
peptide gene, a DNA sequence encoding amino acid lysine is
inserted, with the purpose of Achromobacter protease I digestion at
the junction of the fused protein.
[0013] The termination codon(s) may include conventionally employed
termination codon (e.g. TAG, TGA, etc.).
[0014] The replicatable unit is a DNA sequence capable of
replicating the whole DNA sequence belonging thereto in the host
cells and may include natural plasmid, artificially modified
plasmid (e.g. DNA fragment prepared from natural plasmid) and
synthetic plasmid and preferred examples of the plasmid may include
plasmid pBR 322 or artificially modified thereof (DNA fragment
obtained from a suitable restriction enzyme treatment of pBR 322).
The replicatable unit may contain natural or synthetic terminator
(e.g. synthetic fd phage terminator, etc.).
[0015] Synthetic preparation of promoter-operater region,
initiation codon, protective peptide gene, .alpha.-hANP gene and
termination codon can be prepared in a conventional manner as
generally employed for the preparation of polynucleotides.
[0016] The promoter-operater region, initiation codon, protective
peptide gene, .alpha.-hANP gene and termination codon(s) can
consecutively and circularly be linked with an adequate
replicatable unit (plasmid) together, if desired using an adequate
DNA fragment(s) (e.g. linker, other restriction site, etc.) in a
conventional manner (e.g. digestion with restriction enzyme,
phosphorylation using T4 polynucleotide kinase, ligation using T4
DNA-ligase) to give an expression vector.
[0017] The expression vector can be inserted into a microorganism
(host cell). The insertion can be carried out in a conventional
manner (e.g. transformation, microinjection, etc.) to give a
transformant.
[0018] For the production of .alpha.-hANP in the process of this
invention, thus obtained transformant comprising the expression
vector is cultured in a nutrient medium.
[0019] The nutrient medium contains carbon source(s) (e.g. glucose,
glycerine, mannitol, fructose, lactose, etc.) and inorganic or
organic nitrogen source(s) (ammonium sulfate, ammonium chloride,
hydrolysate of casein, yeast extract, polypeptone, bactotrypton,
beef extracts, etc.). If desired, other nutritious sources (e.g.
inorganic salts (e.g. sodium or potassium biphosphate, dipotassium
hydrogen phosphate, magnesium chloride, magnesium sulfate, calcium
chloride), vitamins (e.g. vitamin B1), antibiotics (e.g.
ampicillin), etc.) may be added to the medium.
[0020] The culture of transformant may generally be carried out at
pH 5.5-8.5 (preferably pH 7-7.5) and 18-40.degree. C. (preferably
25-38.degree. C.) for 5-50 hours.
[0021] Since thus produced protective peptide-fused .alpha.-hANP
generally exists in cells of the cultured transformant, the cells
are collected by filtration or centrifuge, and cell wall and/or
cell membrane thereof is destroyed in a conventional manner (e.g.
treatment with super sonic waves and/or lysozyme, etc.) to give
debris. From the debris, the protective peptide-fused .alpha.-hANP
can be purified and isolated in a conventional manner as generally
employed for the purification and isolation of natural or synthetic
proteins (e.g. dissolution of protein with an appropriate solvent
(e.g. 8M aqueous urea, 6M guanidine, etc.), dialysis, gel
filtration, column chromatography, high performance liquid
chromatography, etc.).
[0022] The .alpha.-hANP can be prepared by cleaving the protective
peptide-fused .alpha.-hANP in the presence of an appropriate
protease (e.g. Achromobacter Protease I(AP I), etc.) treatment or
chemical method (e.g. treatment with cyanogen bromide). In the case
where C-terminal of the protective peptide is lysine, there can
preferably be employed treatment with API. Although API is a known
enzyme (Cf. Biochim. Biophys. Acta., 660, 51 (1981)), it has never
been reported that fused proteins prepared via recombinant DNA
technology can preferably be cleaved by the treatment with API.
This method may preferably be employed for cleaving a fused protein
composed of peptides having a lysine between a protective peptide
and a target peptide having no lysine in its molecule.
[0023] The cleavage of the fused protein may be carried out at pH
5-10 and 20-40.degree. C. (preferably 35-40.degree. C.) for 2-15
hours in an aqueous solution (e.g. buffer solution, aqueous urea,
etc.).
[0024] In the working Examples as mentioned below, the fused
protien is treated with API firstly in a buffer solution containing
8M urea at pH 5, secondly, in a buffer solution containing 4M urea
at pH 9. In this condition, the fused protein is cleaved at lysine
site, and the produced .alpha.-hANP is refolded spontaneously.
[0025] Thus produced .alpha.-hANP can be purified and isolated from
the resultant reaction mixture in a conventional manner as
mentioned above.
[0026] The Figures attached to this specification are explained as
follows.
[0027] In the some of Figures, oligonucleotides are illustrated
with the symbol z,1 or (in this symbol, the mark .circle-solid.
means 5'-phosphorylated end by T4 polynucleotide kinase), and
blocked oligonucleotides are illustrated with the symbol, or (in
this symbol, the mark .DELTA. means ligated position).
[0028] In the DNA sequence in this specification, A, G, C and T
mean the formula: 2
[0029] respectively, and
[0030] 5'-terminal A, G, C and T mean the formula: 3
[0031] respectively, and
[0032] 3-terminal A, G, C and T mean the formula; 4
[0033] respectively, unless otherwise indicated.
[0034] In the following Examples, following abbreviations are
used.
[0035] Ap, Gp, Cp and Tp mean the formula: 5
[0036] respectively, and
[0037] 3'-teminal AOH, GOH, COH and TOH mean the formula: 6
[0038] respectively, and
[0039] 5'-terminal HOAp, HOGp, HOCp and HOTp mean the formula:
7
[0040] respectively, and
[0041] A.sup.Bzpo, G.sup.iBpo, C.sup.Bzpo, Tpo and TO mean the
formula: 89
[0042] respectively, and
[0043] DMTR is dimethoxytrityl, and
[0044] CE is cyanoethyl.
[0045] Mono (or di, or tri)mer (of oligonucleotides) can be
prepared by, for examples the Hirose's method [Cf. Tanpakushitsu
Kakusan Kohso 25, 255 (1980)] and coupling can be carried out, for
examples on cellulose or polystyrene polymer by a phosphotriester
method [Cf. Nucleic Acid Research, 9, 1691 (1981), Nucleic Acid
Research 10, 1755 (1982)].
[0046] The following Examples are given for the purpose of
illustrating this invention, but not limited thereto.
[0047] In the Examples, all of the used enzymes (e.g. restriction
enzyme, T4 polynucleotide kinase, T4 DNA ligase) are commercially
available and conditions of usage of the enzymes are obvious to the
person skilled in the art, for examples, referring to a
prescription attached to commercially sold enzymes.
[0048] Further, in the Examples, the term "polystyrene polymer"
means aminomethylated polystyrene.HCl, divinylbenzene 1%, 100-200
mesh (sold by Peptide Institute Inc.)
EXAMPLE 1
[0049] Synthesis of HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH (AH7)
[0050] (1) Synthesis of DMTrOTpoC.sup.BzpoTO-succinyl-polystyrene
polymer
[0051] i) Preparation of HOTO-succinyl polystyrene polymer:
[0052] To a DMTrO-TO-succinyl-polystyrene polymer (51.8 mg,
10.37.mu. mole) (prepared by the method described in Nucleic Acid
Research 10, 1755 (1982)) in a reaction syringe, 5% dichloroacetic
acid (DCA) solution in dichloromethane (2 ml) was added. After the
standing for 1 minute, the mixture was filtered through filter
glass by nitrogen gas. The DCA treatment was repeated more two
times. The polymer was washed with dichloromethane (2 ml.times.3),
methanol (2 ml.times.3) and pyridine (2 ml.times.3) succesively,
and dried by nitrogen gas stream to give polymer adduct I.
[0053] ii) Preparation of DMTrOTpoC.sup.Bzpo-:
[0054] DMTrOTpoC.sup.Bzpo-CE (32.4 mg, 8.12 .mu.mole) prepared by
the method described in Tanpakushitsu Kakusan Kohso 25, 255 (1980)
was treated with a mixture of triethylamine and acetonitrile (1:1
v/v, 5 ml) at room temperature for 30 minutes. The phosphodiester
dimer (DMTrOTpOC.sup.Bzpo-) thus obtained was dried, water being
separated as the pyridine azeotrope (2 ml.times.2).
[0055] iii) Coupling:
[0056] The dimer (DMTrOTpoC.sup.Bzpo-) and mesitylen
sulfonylnitrothiazolide (MSNT) (80 mg) were dissolved in pyridine
(0.5 ml). The solution was added into the reaction syringe with the
polymer adduct I, and the mixture was shaked for 1 hour at room
temperature. The reaction mixture was filtered through filter glass
by nitrogen gas, and washed with pyridine (2 ml.times.3) to give
the polymer adduct II.
[0057] iv) Acetylation of Unreacted 5'-hydroxy Groups:
[0058] To the polymer adduct II obtained as above, pyridine (0.9
ml) and acetic anhydride (0.1 ml) were added and the mixture was
shaked for 15 minutes. Then the reaction solution was removed
through filter glass and the resultant polymer was washed
successively with pyridine (2 ml.times.3), methanol (2 ml.times.3)
and dichloromethane (2 ml.times.3), and then dried by nitrogen gas
stream. The polymer adduct
(DMTrOTpoC.sup.BzpoTO-succinyl-polystyrene polymer) can use for the
next coupling step.
[0059] (2) Synthesis of
DMTrOTpoC.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succin- yl-polystyrene
polymer:
[0060]
DMTrOTpoC.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-polystyrene
polymer was synthesized from
DMTrOTpoC.sup.BzpoTO-succinyl-polystyrene polymer and
DMTrOTpoC.sup.BzpoC.sup.BzpoCE (44.9 mg) according to similar
conditions as above (1).
[0061] (3) Synthesis of
DMTrOA.sup.BzpoG.sup.iBpoA.sup.BzpoTpoC.sup.BzpoC.-
sup.BzpoTpo-C.sup.BzpoTO-succinyl-polystyrene polymer:
[0062]
DMTrOA.sup.BzpoG.sup.iBpoA.sup.BzpoTpoC.sup.BzpoC.sup.BzpoTpoC.sup.-
BzpoTO-succinyl-polystyrene polymer was synthesized from
DMTrOTpoC.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-polystyrene
polymer and DMTrOA.sup.BzpoG.sup.iBpoA.sup.BzpoCE (48.5 mg)
according to similar conditions as above (1).
[0063] (4) Synthesis of
DMTrOC.sup.BzpoG.sup.iBpoTpoA.sup.BzpoG.sup.iBpoA.-
sup.BzpoTpo-C.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-polystyrene
polymer:
[0064]
DMTrOC.sup.BzpoG.sup.iBpoTpoA.sup.BzpoG.sup.iBpoA.sup.BzpoTpoC.sup.-
BzpoC.sup.BzpoTpo-C.sup.BzpoTO-succinyl-polystyrene polymer was
synthesized from
DMTrOA.sup.BzpoG.sup.iBpoA.sup.BzpoTpoC.sup.BzpoC.sup.Bz-
poTpoC.sup.BzpoTO-succinyl-polystyrene polymer and
DMTrOC.sup.BzpoG.sup.iB- poTpoCE (45.1 mg) according to similar
conditions as above (1).
[0065] (5) Synthesis of
DMTrOC.sup.BzpoTpoG.sup.iBpoC.sup.BzpoG.sup.iBpoTp-
oA.sup.Bzpo-G.sup.iBpoA.sup.BzpoTpoC.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-suc-
cinyl-polystyrene polymer:
[0066]
DMTrOC.sup.BzpoTpoG.sup.iBpoC.sup.BzpoG.sup.iBpoTpoA.sup.BzpoG.sup.-
iBpoA.sup.BzpoTpo-C.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-polystyrene
polymer (60 mg) was synthesized from
DMTrOC.sup.BzpoG.sup.iBpoTpoA.sup.Bz-
poG.sup.iBpoA.sup.BzpoTpo-C.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-pol-
ystyrene polymer and DMTrOC.sup.BzpoTpoG.sup.iBpoCE (45.1 mg)
according to similar conditions as above (1). At this final step,
unreacted 5'-hydroxy group was not necessary to protect with an
acetyl group.
[0067] (6) Synthesis of HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH:
[0068]
DMTrOC.sup.BzpoTpoG.sup.iBpoC.sup.BzpoG.sup.iBpoTpoA.sup.BzpoG.sup.-
iBpoA.sup.BzpoTpo-C.sup.BzpoC.sup.BzpoTpoC.sup.BzpoTO-succinyl-polystyrene
polymer (60 mg) was treated with 1M
N,N,N',N'-tetramethyleneguanidium pyridine 2-aldoximate (in
dioxane-water (1:1: v/v, 1 ml)) at 37.degree. C. for 20 hours in a
sealed tube. To the reaction mixture 28% (w/w) aqueous ammonia (12
ml) was added, and the mixture was heated at 60.degree. C. for 5
hours. The solid polymer was removed by filtration and washed with
water (10 ml). The filtrate and washed solution were evaporated to
dryness, and the residue was treated with 80% aqueous acetic acid
(25 ml) at room temperature for 15 minutes. After removal of the
solvent, the residue was dissolved in 0.1M triethylammonium
carbonate buffer (pH 7.5, 25 ml) was washed with diethylether
(3.times.25 ml). Aqueous layer was evaporated to dryness and the
residue was dissolved in 0.1M triethylammonium carbonate buffer (pH
7.5, 2 ml) to yield curde HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH in the
solution.
[0069] (7) Purification of HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH
[0070] i) First purification of the crude product was performed by
column chromatography on Biogel P2 (Biolad) (24.times.2.6 cm ID).
The fractions corresponding to the first eluted peak (50 mM
ammonium acetate containing 0.1 mM EDTA, flow rate: 1 ml/min) were
collected and freeze-dried to give the first purified product.
[0071] ii) Second purification of the first purified product was
performed by high performance liquid chromatography (HPLC) on
CDR-10 (Mitsubishi Kasei) (25 cm.times.4.6 mm ID) using a linear
gradient of 1M ammonium acetate-10% (v/v) aqueous ethanol to 4.5 M
ammonium acetate-10% (v/v) aqueous ethanol (80 minutes, flow rate:
1 ml/minute, 60.degree. C.) to give the second purified
product.
[0072] iii) Third purification of the second purified product was
performed by reverse phase HPLC (Rp-18-5.mu.(.times.77) (Merck), 15
cm.times.4 mm ID) using a linear gradient of 0.1 M ammonium acetate
to 0.1 M ammonium acetate-15% (v/v) aqueous acetonitrile (40
minutes, 1.5 ml/minute, room temperature) to give the final
purified product.
[0073] (HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH)
[0074] (8) Analysis of oligonucleotide:
[0075] (HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH)
[0076] i) Digestion by phosphodiesterase
[0077] The mixture of HOCpTpGpCpGpTpApGpApTpCpCpTpCpTOH (10 .mu.g,
5.1 .mu.l), 0.2M MgCl.sub.2 (20 .mu.l), 0.2M tris-HCl (pH8.5) (20
.mu.l) and 0.1 mM EDTA (144.9 .mu.l) was treated with
phosphodiesterase (10 unit, 10 .mu.l) at 37.degree. C. for 20
minutes, and then heated at 100.degree. C. for 2 minutes.
[0078] ii) Analysis by HPLC:
[0079] The oligonucleotide in the reaction mixture was analyzed by
HPLC (CDR-10 (Mitsubishi Kasei), 25 cm.times.4.6 mm ID) using a
linear gradient of water to 2.0 M ammonium acetate (pH 3.4) (40
minutes, flow rate: 1.5 ml/minute, 60.degree. C.). From each peak
area observed, its nucleotide composition was determined comparing
with area of a standard sample.
[0080] Calcd: pCOH 4.000, pAOH 2.000, pTOH 5.000, pGOH 3.000
[0081] Observed: pCOH 3.770, pAOH 2.026, pTOH 5.237, pGOH 2.968
EXAMPLE 2
[0082] Synthesis of oligonucleotide:
[0083] Following oligonucleotides were prepared in a similar manner
to that described in Example 1.
1 (1) HOApGpCpTpTpGpApApGpTpTpGpApGpCpApTpGOH (AH1) (2)
HOApApTpTpCpApTpGpCpTpCpApApCpTpTpCpAOH (AH2) (3)
HOApApTpTpCpGpGpTpApTpGpGpGpCOH (AH3) (4)
HOTpTpCpApCpCpGpCpCpCpApTpApCpCpGOH (AH4) (5)
HOGpGpTpGpApApGpCpTpApApApTpCpTOH (AH5) (6)
HOCpGpCpApGpApGpApTpTpTpApGpCOH (AH6) (7)
HOApApGpCpApApGpApGpGpApTpCpTpAOH (AH8) (8)
HOTpGpCpTpTpTpGpGpTpGpGpCpCpGpTOH (AH9) (9)
HOTpCpCpApTpApCpGpGpCpCpApCpCpAOH (AH10) (10)
HOApTpGpGpApCpCpGpCpApTpCpGpCpTOH (AH11) (11)
HOTpGpApGpCpApCpCpGpApTpGpCpGpGOH (AH12) (12)
HOGpCpTpCpApGpTpCpCpGpGpTpCpTpGOH (AH13) (13)
HOCpApGpCpCpCpApGpApCpCpGpGpApCOH (AH14) (14)
HOGpGpCpTpGpTpApApCpTpCpTpTpTpCOH (AH15) (15)
HOTpApApCpGpGpApApApGpApGpTpTpAOH (AH16) (16)
HOCpGpTpTpApCpTpGpApTpApGOH (AH17) (17) HOGpApTpCpCpTpApTpCpApGOH
(AH18)
EXAMPLE 3
[0084] Synthesis of oligonucleotides:
[0085] Following oligonucleotides were prepared by a similar manner
to that of Example 1.
2 (1) HOApApTpTpTpGpCpCpGpApCpAOH (A) (2)
HOCpGpTpTpApTpGpApTpGpTpCpGpGpCpAOH (B) (3)
HOTpCpApTpApApCpGpGpTpTpCpTpGpGpCOH (C) (4)
HOGpApApTpApTpTpTpGpCpCpApGpApApCOH (D) (5)
HOApApApTpApTpTpCpTpGpApApApTpGpAOH (E) (6)
HOTpCpApApCpApGpCpTpCpApTpTpTpCpAOH (F) (7)
HOGpCpTpGpTpTpGpApCpApApTpTpApApTOH (G) (8)
HOGpTpTpCpGpApTpGpApTpTpApApTpTpGOH (H) (9)
HOCpApTpCpGpApApCpTpApGpTpTpApApCOH (I) (10)
HOGpCpGpTpApCpTpApGpTpTpApApCpTpAOH (J) (11)
HOTpApGpTpApCpGpCpApApGpTpTpCpApCOH (K) (12)
HOCpTpTpTpTpTpApCpGpTpGpApApCpTpTOH (L) (13)
HOGpTpApApApApApGpGpGpTpApTOH (M') (14) HOCpGpApTpApCpCOH (N') (15)
HOGpTpApApApApApGpGpGpTpApTpCpGOH (M) (16)
HOApApTpTpCpGpApTpApCpCOH (N) (17) HOApApTpTpCpApTpGpGpCpTOH (SA)
(18) HOGpGpTpTpGpTpApApGpApApCpTpTpCpTOH (SB) (19)
HOTpTpTpGpGpApApGpApCpTpTpTOH (SC) (20)
HOCpApCpTpTpCpGpTpGpTpTpGpApTpApGOH (SD) (21)
HOTpTpApCpApApCpCpApGpCpCpApTpGOH (SE) (22)
HOCpCpApApApApGpApApGpTpTpCOH (SF) (23)
HOCpGpApApGpTpGpApApApGpTpCpTpTOH (SG) (24)
HOGpApTpCpCpTpApTpCpApApCpAOH (SH)
EXAMPLE 4
[0086] Synthesis of oligonucleotides:
[0087] Following oligonucleotides were prepared by a similar manner
to that of Example 1.
3 (1) HOApApCpTpApGpTpApCpGpCOH (Np1) (2)
HOApApCpTpTpGpCpGpTpApCpTpApGpTpTOH (Np4) (3)
HOApApGpTpTpCpApCpGpTpApApApApApGOH (Np2) (4)
HOApTpApCpCpCpTpTpTpTpTpApCpGpTpGOH (Np5) (5)
HOGpGpTpApTpCpGpApTpApApApApTpGOH (Np3) (6)
HOGpTpApGpApApCpApTpTpTpTpApTpCpGOH (Np6) (7)
HOTpTpCpTpApCpTpTpCpApApCpApApAOH (Cd1) (8)
HOGpGpTpCpGpGpTpTpTpGpTpTpGpApAOH (Cd2) (9)
HOCpCpGpApCpCpGpGpCpTpApTpGOH (Cd3) (10)
HOGpCpTpGpGpApGpCpCpApTpApGpCpCOH (G2) (11)
HOGpCpTpCpCpApGpCpTpCpTpCpGpTpCOH (H1) (12)
HOCpGpGpTpGpCpGpCpGpApCpGpApGpAOH (H2) (13)
HOGpCpGpCpApCpCpGpCpApGpApCpTpGOH (I1) (14)
HOGpApTpApCpCpApGpTpCpTpGOH (Cd4) (15) HOGpTpApTpCpGpTpApGpApCpGOH
(Cd5) (16) HOApCpCpCpTpCpGpTpCpTpApCOH (Cd6) (17)
HOApGpGpGpTpGpGpCpGpApTpGOH (Cd7) (18) HOApApTpTpCpApTpCpGpCpCOH
(Cd8)
EXAMPLE 5
[0088] Construction and Cloning of the Synthetic trp promoter II
Gene (as Illustrated in FIGS. 6 and 7):
[0089] The trp promoter II gene was constructed by the similar
method as described in Example 7 (as illustrated in FIG. 6). The
synthetic gene was ligated with EcoRI-BamHI fragment of pBR322
(commercially available: Takarashuzo, NEB, etc.) and then E. coli
HB101 (ATCC 33694) was transformed with the ligation product. The
plasmid obtained from the transformant of .sup.RAmp and .sup.STet
was digested with HpaI to confirm a band (4.1 kbp), and then
digested with BamHI to confirm a band of 90 b.p. on PAGE. Moreover,
the fragment of 56 b.p. by EcoRI-BamHI digestion was confirmed by
the comparison with size marker on PAGE. This plasmid was named
pTrpEB7 and used construction of expression vector.
EXAMPLE 6
[0090] Construction and Cloning of trp promoter vector (pBR322trp)
(as Illustrated in FIG. 8):
[0091] Plasmid pBR322 (9 .mu.g) was digested with EcoRI and BamHI
restriction endnucleases. Reaction was terminated by heating at
65.degree. C. for 5 minutes and the fragments were separated by
electrophoresis on a 0.8% agarose gel to give the small fragment
(500 ng) of 375 b.p. On the other hand, plasmid pTrpEB7 (10 .mu.g)
was digested with EcoRI and BamHI, followed by preparative gel
electrophoresis to give the large fragment (5 .mu.g) of 4094 b.p.
The pTrpEB7 EcoRI-BamHI fragment (4094 b.p., 200 .mu.g) was ligated
with the pBR322 EcoRI-BamHI fragment (375 b.p., 100 ng) in the
ligation buffer (50 mM Tris-HCl (pH 7.6), 10 mM MgCl.sub.2, 20 mM
DTT, 1 mM ATP, 1 mM spermidine, 50 .mu.g/ml BSA) (20 .mu.l)
containing T4 DNA ligase. (Takarashuzo: 360 unit) at 15.degree. C.
overnight. The ligated mixture was transformed into E. coli HB101
by Kushiner's method (Cf. T. Maniatis et al Molecular Cloning p252
(1982), Cold Spring Harbor Laboratory) and tetracycline resistant
transformants were obtained on the plate containing tetracycline
(25 .mu.g/ml). The plasmid pBR322trp isolated from the transformant
was digested with EcoRI-BamHI (375 b.p., 4094 b.p.) and HpaI (4469
b.p.) to confirm the trp promoter gene by 7.5% PAGE and 0.8%
agarose gel electrophoresis.
EXAMPLE 7
[0092] Construction of the Synthetic trp promoter III Gene (as
Illustrated in FIG. 9):
[0093] Each oligonucleotides (B-M') (each 0.2 n mole) of block I',
II' and III' were phosphorylated with T4 polynucleotide kinase
(BRL; 2.5 unit) in the ligation buffer (70 .mu.l) at 37.degree. C.
for 1 hour. To the reaction mixture of each blocks T4 DNA ligase
(300 unit) and 20 mM ATP (2 .mu.l) were added, and the mixture was
incubated at 15.degree. C. for 30 minutes. The reaction was
terminated by heating at 65.degree. C. for 10 minutes. The reaction
mixture of these blocks (I', II' and III') was put together and
mixed with unphosphorylated oligonucleoties (A, N') in the presence
of T4 DNA ligase (360 unit) and 20 mM ATP (2 .mu.l). After the
incubation of the mixture at 15.degree. C. for 1 hour, the last
ligation product was purified by 2-16% gradient polyacrylamide gel
electrophoresis (PAGE) to give the 106 b.p. synthetic trp promoter
III gene.
EXAMPLE 8
[0094] Construction and Cloning of Double trp promoter vector
(p322dtrpS)(as Illustrated in FIG. 10):
[0095] Plasmid pBR322trp was digested with EcoRI and ClaI, followed
by preparative agarose gel electrophoresis to give the large
fragment of 4446 b.p. This fragment (4446 b.p.) was ligated with
trp promoter III gene (106 b.p.) obtained in Example 7 in the
presence of T4 DNA ligase. The ligated mixture was transformed into
E. coli HB101 to give the transformants of ampicillin and
tetracycline resistance. The plasmid p322dtrpS obtained from the
transformant was confirmed by restriction endonuclease analysis
ClaI-BamHI (352 b.p.), HpaI (107 b.p.) and AatII-ClaI (287
b.p.).
EXAMPLE 9
[0096] Construction of Peptide Cd Gene With a Part of DNA Fragment
of Synthetic trp promoter III (as Illustrated in FIGS. 11 and
12):
[0097] Each oligonucleotides (0.2 n mole) (Np1-Cd8, shown in
Example 4) of block I", II" and III" were phosphorylated with T4
polynucleotide kinase (2.5 unit) in ligation buffer (60 .mu.l) at
37.degree. C. for 1 hour. To the reaction mixture of each block T4
DNA ligase (360 unit) and ATP (2 .mu.l) was added, the mixture was
incubated at 15.degree. C. for 1 hour. The reaction mixture of
these blocks (I", II" and III") was put together and incubated with
T4 DNA ligase (360 unit) and 20 mM ATP (2 .mu.l) at 15.degree. C.
overnight, and then heated at 80.degree. C. for 10 minutes. To the
mixture 500 mM NaCl (20 .mu.l) and EcoRI (20 unit) were added.
After the incubation at 37.degree. C. for 2 hours, the last
ligation product was purified by 15% PAGE to give the peptide Cd
gene with a part of DNA fragment of synthetic trp promoter III (125
b.p.), DNA sequence of which is illustrated in FIG. 12.
EXAMPLE 10
[0098] Construction and Cloning of plasmid pCd.gamma. (as
Illustrated in FIG. 13):
[0099] Plasmid p.gamma.trp(4544 b.p.) (Cf. GB2164650A published on
Mar. 26, 1986; Escherichia coli F-9 containing this plasmid
p.gamma.trp has been depositing with. FRI(Japan) under the number
FERM BP-905 from Sep. 20, 1984) was digested with HpaI and EcoRI to
give a large fragment (4510 b.p.), which was ligated with the
peptide Cd gene with a part of DNA fragment of synthetic trp
promoter III (125 b.p.) as obtained in Example 9 in the presence of
T4 DNA ligase. The ligated mixture was transformed into E. coli
HB101. The plasmid (pCd.gamma.) obtained from the transformant of
.sup.RAmp was confirmed by restriction endonuclease analysis:
[0100] ClaI-BamHI (543 b.p.), ClaI-HindIII (273 b.p.), ClaI-EcoRI
(93 b.p.) and AatII-ClaI (180 b.p.).
EXAMPLE 11
[0101] Construction and Cloning of plasmid pCd.gamma.trpSd (as
Illustrated in FIG. 14):
[0102] The plasmid pCd.gamma. was digested with ClaI and BamHI to
give the smaller fragment (543 b.p.), which was ligated with the
ClaI-BamHI fragment (4223 b.p.) of p322dtrpS (Example 7) in the
presence of T4 DNA ligase. The ligated mixture was transformed into
E. coli HB101. The plasmid (pCd.gamma.trpSd) obtained from the
transformant of .sup.RAmp was confirmed by restriction endonuclease
analysis:
[0103] HpaI-BamHI (107,575 b.p.), ClaI-BamHI (543 b.p.),
[0104] PstI-EcoRI (1057 b.p.), EcoRI-BamHI (450 b.p.)
[0105] HindIII-BamHI (270 b.p.), ClaI-HindIII (273 b.p.)
EXAMPLE 12
[0106] Preparation of .alpha.-hANP Gene With Linker DNA (as
Illustrated in FIG. 15):
[0107] Each oligonucleotides (AH2-AH17) (each 0.2 n mole) of block
I and II were phosphorylated with T4 polynucleotide kinase (2.5
unit) in the ligation buffer (70 .mu.l) at 37.degree. C. for 1
hour. To the reaction mixture of each blocks T4 DNA ligase (300
unit) and 20 mM ATP (2 .mu.l) were added, and the mixture was
incubated at 15.degree. C. for 30 minutes. The reaction was
terminated by heating at 65.degree. C. for 10 minutes. The reaction
mixture of two blocks (I'" and II'") was put together and mixed
with unphosphorylated oligonucleotides (AH1, AH18) in the presence
of T4 DNA ligase (300 unit) and 20 mM ATP (2 .mu.l). After the
incubation of the mixture at 15.degree. C. for 1 hour, the last
ligation product was purified by 2-16% gradient PAGE to give the
134 b.p. .alpha.-hANP gene with linker DNA (as illustrated in FIG.
5).
EXAMPLE 13
[0108] Construction and Cloning of .alpha.-hANP Expression Vector
pCLaHtrpSd (as Illustrated in FIG. 16):
[0109] The plasmid pCd.gamma.trpSd was digested with HindIII and
BamHI to give the larger fragment (4743 b.p.), which was ligated
with the .alpha.-hANP gene with linker DNA (134 b.p.) in the
presence of T4 DNA ligase. The ligated mixture was transformed into
E. coli HB101 to give a transformant H1. The plasmid (pCLaHtrpSd)
(which contains CLaH protein(peptide CLa-fused .alpha.-hANP
protein)gene, DNA sequence of which is illustrated in FIG. 17)
obtained from the transformant of .sup.RAmp (E. coli H1) was
confirmed by restriction endonuclease analysis:
[0110] AatII-ClaI (287 b.p.), ClaI-BamHI (407 b.p.),
[0111] ClaI-EcoRI (93, 198 b.p.), EcoRI-BamHI (116, 198 b.p.),
HindIII-BamHI (134 b.p.), HpaI-BamHI (107, 439 b.p.).
EXAMPLE 14
[0112] Expression of a Gene Coding for the peptide CLa-Fused
.alpha.-hANP (CLaH Protein):
[0113] An overnight culture of E. coli H1 containing the expression
vector, plasmid pCLaHtrpSd in L broth (20 ml) containing 50
.mu.g/ml ampicillin was diluted in M9 medium (400 ml) containing
0.2% glucose, 0.5% casamino acid (acid-hydrolyzed casein), 50
.mu.g/ml vitamin B1 and 25 .mu.l/ml ampicillin, and the E. coli was
cultured at 37.degree. C. When A600 (absorbance at 600 nm) of the
cultured broth was 0.5, .beta.-indole acrylic acid (2 mg/ml
ethanol; 2 ml) was added and the cells were incubated for 3 hours
(final A600=1.85). Then the cells were harvested by centrifugation
(6000 rpm, 4.degree. C., 5 minutes).
EXAMPLE 15
[0114] Isolation and Purification of .alpha.-hANP:
[0115] (1) Isolation and Purification of the peptide CLa-Fused
.alpha.-hANP (CLaH Protein)
[0116] The wet cell paste from the cultured broth (600 ml) as
prepared in Example 14 was suspended in 8 ml of 10 mM PBS-EDTA (pH
7.4) (NaCl (8.0 g), KCl (0.2 g), Na.sub.2HPO4 12H.sub.2O (2.9 g),
KH.sub.2PO.sub.4 (0.2 g), EDTA (3.73 g)/liter) and cells were
destroyed by sonication at 0.degree. C. The pellet was collected by
centrifugation at 15,000 rpm for 20 minutes (4.degree. C.), and
suspended in 8 ml of 6M guanidine-HCl, 10 mM PBS-EDTA and 2 mM
.beta.-mercaptoethanol and the suspension was treated by super
sonication at 0.degree. C. The suspension was centrifuged at 15,000
rpm for 20 minutes (4.degree. C.) and the supernatant was dialyzed
overnight at 4.degree. C. against 10 mM pBS-EDTA solution
containing p-nitrophenyl methylsulfonyl fluoride (PMSF). After the
fraction dialyzed was centrifuged (15,000 rpm, 4.degree. C., 20
minites), the pellet was dissolved in 100 mM Tris-HCl buffer (pH
8.0) (8 ml) containing 6M guanidine-HCl, 10 mM EDTA and 100 mM
dithiothreitol and the solution was stood overnight. The solution
was dialyzed against 1M acetic acid (0.5 liters) containing 10 mM
2-mercaptoethanol twice and adjusted to pH 8.0 with
trisaminomethane. The resulting precipitate (fused protein; 15.2
mg) was collected by centrifugation (3.000 rpm, 10 minutes), and
washed with 10 mM sodium acetate buffer (pH 5.0).
[0117] (2) Elimination of peptide CLa from the peptide CLa Fused
.alpha.-hANP with Achromobacter protease I(API):
[0118] The fused protein obtained above was suspended in 10 mM
sodium acetate buffer (pH 5.0) (30 ml) containing 8M urea, the
suspension was incubated with Achromobactor protease I(API) (0.25
unit) (Wako pure chemical industries, Ltd) at 37.degree. C. for 2
hours. The reaction mixture was diluted with distilled water (30
ml), adjusted to pH 9.0 with trisaminomethane, and then incubated
with additional API (0.25 unit) at 37.degree. C. for 2 hours. The
reaction solution was diluted with 10 mM sodium phosphate buffer
(pH 7.0) (120 ml), and adjusted to pH 7 with acetic acid. The
solution was applied to a Sp-sephadex C-25 column (15 ml)
equilibrated with 10 mM solium phosphate buffer (pH 7.0). The
column was washed with the same buffer, and eluted with 10 mM
sodium phosphate buffer (pH 8.0) containing 0.5M aqueous sodium
chloride to collect the fractions containing a partial purified
.alpha.-hANP (0.4 mg).
[0119] (3) High Performance Liquid Chromatography (HPLC):
[0120] The pooled fraction obtained in the above (2) was
concentrated in vacuo, dialyzed against water (300 ml), and
purified by reverse phase HPLC to give a pure .alpha.-hANP (0.3
mg).
4 HPLC condition (preparation) column: Beckman Ultrapore semi-prep.
(.phi.10 .times. 250 mm) flow rate: 2.5 ml/minute elution: linear
gradient from 10% to 60% acetonitrile in 0.01 M trifluoroacetic
acid over 50 minutes. monitor absorbance at 214 nm (analysis)
column: Beckmann Ultrapore RPSC (.phi. 4.6 .times. 75 mm) flow
rate: 1 ml/minute elution: same condition as the preparation
retention time: 11.9 minutes
[0121] The .alpha.-hANP was supperimposed with authentic
.alpha.-hANP (sold by Funakoshi)
[0122] (4) Amino Acid Analysis of .alpha.-hANP
[0123] The sample was reduced and carboxymethylated, and then
hydrolyzed with 6N HCl at 110.degree. C. for 24 hours. The amino
acid composition of .alpha.-hANP was obtained using a Waters amino
acid analysis system.
[0124] Amino acid compositions (residues per mole) of .alpha.-hANP
were coincided with the expected values.
[0125] (5) Amino Acid Sequence Analysis of .alpha.-hANP
[0126] The N-terminal amino acid sequence of .alpha.-hANP was
determined by Edman's method (DABITC method) [described in FEBS
Lett., 93,205 (1978)] to confirm N-terminal Ser and Leu sequence.
C-terminal amino acids (Ser-Phe-Arg-Tyr) were determined by the
digestion with carboxypeptidase and the followed amino acid
analysis using a Waters amino acid analysis system. The whole amino
acid sequence of .alpha.-hANP obtain in the above Example was
determined by using both procedures and was identical with the
known sequence of .alpha.-hANP.
EXAMPLE 16
[0127] Construction and Cloning of plasmid pBR322trpSs (as
Illustrated in FIG. 18):
[0128] Plasmid pBR322 was digested with EcoRI and ClaI. The large
fragment (4340 bp) was purified by 0.8% agarose gel
electrophoresis, and ligated to the synthetic trp promoter III gene
in the presence of T4 DNA ligase and 1 mM ATP. The ligation mixture
was used to transform E. coli HB101. The plasmid DNA (pBR322trpSs)
was isolated from a transformed clone .sup.RAmp) and charactarized
by restriction endonuclease analysis.
[0129] Analysis data: Hpa I; 4445 bp, ClaI-Pst I; 834 bp
EXAMPLE 17
[0130] Construction and Cloning of plasmid pCLaHtrp-2 (as
Illustrated in FIG. 19):
[0131] Plasmid pCLaHtrpSd was digested with ClaI and BamHI. The
small fragment (407 bp) was isolated. On the other hand pBR322trpSs
was digested with ClaI and BamHI. The larger fragment (4093 bp) was
isolated and ligated to the former DNA (407 bp). After
transformation of E. coli HB101 with the ligation mixture, the
desired plasmid (pCLaHtrp-2) was isolated from a transformed
clone(.sup.RAmp) and characterized by restriction enzyme analysis:
ClaI-Pst I; 834 bp, ClaI-BamHI; 407 bp
EXAMPLE 18
[0132] Synthesis of oligonucleotides:
[0133] Following oligonucleotides were prepared in a similar manner
to that of Example 1.
5 (1) HOGpApTpCpCpTpCpGpApGpApTpCpApAOH (T1) (2)
HOGpCpCpTpTpTpApApTpTpGpApTpCpTpCpGpApGOH (T2) (3)
HOTpTpApApApGpGpCpTpCpCpTpTpTpTpGpGpAOH (T3) (4)
HOApApApApApGpGpCpTpCpCpApApApApGpGpAOH (T4) (5)
HOGpCpCpTpTpTpTpTpTpTpTpTpTpGOH (T5) (6) HOTpCpGpApCpApApApApAOH
(T6)
EXAMPLE 19
[0134] Construction and Cloning of Synthetic fd phage Terminator
(as Illustrated in FIGS. 20 and 21):
[0135] The synthetic fd phage terminator was constructed by a
similar method as described in Example 7 (as illustrated in FIG.
20).
[0136] Namely, DNA oligomers T2, T3, T4 and T5 (each 0.4 nmole)
were mixed and phosphorylated with T4 polynucleotide kinase in the
presence of 1 mM ATP. The reaction mixture was heated at 65.degree.
C. for 10 minutes to inactivate the enzyme. To the resultant
mixture, DNA oligomer T1 and T6 (each 0.8 nmole) and T4 DNA ligase
were added. The mixture was incubated at 15.degree. C. for 30
minutes, and applied to 2.fwdarw.16% gradient polyacrylamide gel
electrophoresis. The desired DNA fragment (47 bp) was recovered by
electroelution and ligated to the larger fragment of pBR322
digested with BamHI and Sal I (4088 bp). After transformation of E.
coli HB101 with the ligation mixture, the desired plasmid (pter)
was isolated from a transformed clone (.sup.RAmp).
[0137] Restriction enzyme analysis: BamHI-Sal I; 47 bp, Ava I; 817
bp
EXAMPLE 20
[0138] Construction and Cloning of .alpha.-hANP expression vector
plasmid pCLaHtrp3t (as Illustrated in FIG. 22):
[0139] Plasmid pCLaHtrp-2 was digested with Pst I and BamHI. From
the digestion mixture, the small fragment (1241 bp) was isolated
and ligated to the large fragment of pter 21 obtained from
digestion of pter 21 with Pst I and BamHI (3005 bp).
[0140] The ligation mixture was transformed into E. coli HB101 to
give a transformant E. coli H2. The plasmid CLaHtrp3t (which
contains CLaH protein gene) obtained from the transformant of
.sup.RAmp (E. coli H2) was confirmed by restriction endonuclease
analysis: ClaI-EcoRI; 93 bp, 198 bp, HindIII-BamHI; 134 bp,
PstI-ClaI-XhoI; 834 bp, 411 bp
EXAMPLE 21
[0141] Production of .alpha.-hANP Using E. coli H2:
[0142] .alpha.-hANP was obtained in a similar manner to those of
Example 14 and 15 using E. coli H2 in place of E. coli H1.
[0143] Amino acid sequence of thus obtained .alpha.-hANP was
identical with the known sequence of .alpha.-hANP.
Sequence CWU 1
1
88 1 28 PRT Homo sapiens 1 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly
Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn
Ser Phe Arg Tyr 20 25 2 15 DNA Artificial Sequence synthetic DNA 2
ctgcgtagat cctct 15 3 18 DNA Artificial Sequence synthetic DNA 3
agcyygaagy ygagcayg 18 4 18 DNA Artificial Sequence synthetic DNA 4
aattcatgct caacttca 18 5 14 DNA Artificial Sequence synthetic DNA 5
aattcggtat gggc 14 6 16 DNA Artificial Sequence synthetic DNA 6
ttcaccgccc ataccg 16 7 15 DNA Artificial Sequence synthetic DNA 7
ggtgaagcta aatct 15 8 14 DNA Artificial Sequence synthetic DNA 8
cgcagagatt tagc 14 9 15 DNA Artificial Sequence synthetic DNA 9
aagcaagagg atcta 15 10 15 DNA Artificial Sequence synthetic DNA 10
tgctttggtg gccgt 15 11 15 DNA Artificial Sequence synthetic DNA 11
tccatacggc cacca 15 12 15 DNA Artificial Sequence synthetic DNA 12
atggaccgca tcgct 15 13 15 DNA Artificial Sequence synthetic DNA 13
tgagcaccga tgcgg 15 14 15 DNA Artificial Sequence synthetic DNA 14
gctcagtccg gtctg 15 15 15 DNA Artificial Sequence synthetic DNA 15
cagcccagac cggac 15 16 15 DNA Artificial Sequence synthetic DNA 16
ggctgtaact ctttc 15 17 15 DNA Artificial Sequence synthetic DNA 17
taacggaaag agtta 15 18 12 DNA Artificial Sequence synthetic DNA 18
cgttactgat ag 12 19 11 DNA Artificial Sequence synthetic DNA 19
gatcctatca g 11 20 12 DNA Artificial Sequence synthetic DNA 20
aatttgccga ca 12 21 16 DNA Artificial Sequence synthetic DNA 21
cgttatgatg tcggca 16 22 16 DNA Artificial Sequence synthetic DNA 22
tcataacggt tctggc 16 23 16 DNA Artificial Sequence synthetic DNA 23
gaatatttgc cagaac 16 24 16 DNA Artificial Sequence synthetic DNA 24
aaatattctg aaatga 16 25 16 DNA Artificial Sequence synthetic DNA 25
tcaacagctc atttca 16 26 16 DNA Artificial Sequence synthetic DNA 26
gctgttgaca attaat 16 27 16 DNA Artificial Sequence synthetic DNA 27
gttcgatgat taattg 16 28 16 DNA Artificial Sequence synthetic DNA 28
catcgaacta gttaac 16 29 16 DNA Artificial Sequence synthetic DNA 29
gcgtactagt taacta 16 30 16 DNA Artificial Sequence synthetic DNA 30
tagtacgcaa gttcac 16 31 15 DNA Artificial Sequence synthetic DNA 31
cttttacgtg aactt 15 32 13 DNA Artificial Sequence synthetic DNA 32
gtaaaaaggg tat 13 33 7 DNA Artificial Sequence synthetic DNA 33
cgatacc 7 34 15 DNA Artificial Sequence synthetic DNA 34 gtaaaaaggg
tatcg 15 35 11 DNA Artificial Sequence synthetic DNA 35 aattcgatac
c 11 36 11 DNA Artificial Sequence synthetic DNA 36 aattcatggc t 11
37 16 DNA Artificial Sequence synthetic DNA 37 ggttgtaaga acttct 16
38 13 DNA Artificial Sequence synthetic DNA 38 tttggaagac ttt 13 39
16 DNA Artificial Sequence synthetic DNA 39 cacttcgtgt tgatag 16 40
15 DNA Artificial Sequence synthetic DNA 40 ttacaaccag ccatg 15 41
13 DNA Artificial Sequence synthetic DNA 41 ccaaaagaag ttc 13 42 15
DNA Artificial Sequence synthetic DNA 42 cgaagtgaaa gtctt 15 43 13
DNA Artificial Sequence synthetic DNA 43 gatcctatca aca 13 44 11
DNA Artificial Sequence synthetic DNA 44 aactagtacg c 11 45 16 DNA
Artificial Sequence synthetic DNA 45 aacttgcgta ctagtt 16 46 16 DNA
Artificial Sequence synthetic DNA 46 aagttcacgt aaaaag 16 47 16 DNA
Artificial Sequence synthetic DNA 47 ataccctttt tacgtg 16 48 15 DNA
Artificial Sequence synthetic DNA 48 ggtatcgata aaatg 15 49 16 DNA
Artificial Sequence synthetic DNA 49 gtagaacatt ttatcg 16 50 15 DNA
Artificial Sequence synthetic DNA 50 ttctacttca acaaa 15 51 15 DNA
Artificial Sequence synthetic DNA 51 ggtcggtttg ttgaa 15 52 13 DNA
Artificial Sequence synthetic DNA 52 ccgaccggct atg 13 53 15 DNA
Artificial Sequence synthetic DNA 53 gctggagcca tagcc 15 54 15 DNA
Artificial Sequence synthetic DNA 54 gctccagctc tcgtc 15 55 15 DNA
Artificial Sequence synthetic DNA 55 cggtgcgcga cgaga 15 56 15 DNA
Artificial Sequence synthetic DNA 56 gcgcaccgca gactg 15 57 12 DNA
Artificial Sequence synthetic DNA 57 gataccagtc tg 12 58 12 DNA
Artificial Sequence synthetic DNA 58 gtatcgtaga cg 12 59 12 DNA
Artificial Sequence synthetic DNA 59 accctcgtct ac 12 60 12 DNA
Artificial Sequence synthetic DNA 60 agggtggcga tg 12 61 11 DNA
Artificial Sequence synthetic DNA 61 aattcatcgc c 11 62 15 DNA
Artificial Sequence synthetic DNA 62 gatcctcgag atcaa 15 63 19 DNA
Artificial Sequence synthetic DNA 63 gcctttaatt gatctcgag 19 64 18
DNA Artificial Sequence synthetic DNA 64 ttaaaggctc cttttgga 18 65
18 DNA Artificial Sequence synthetic DNA 65 aaaaaggctc caaaagga 18
66 13 DNA Artificial Sequence synthetic DNA 66 gccttttttt ttt 13 67
10 DNA Artificial Sequence synthetic DNA 67 tcgacaaaaa 10 68 106
DNA Artificial Sequence synthetic trp promoter 68 aattgccgac
atcataacgg ttctggcaaa tattctgaaa tgagctgttg acaattaatc 60
atcgaactag ttaactagta cgcaagttca cgtaaaaagg gtatcg 106 69 164 DNA
Artificial Sequence synthetic trp promoter 69 aatttgccga catcataacg
gttctggcaa atattctgaa atgagctgtt gacaattaat 60 catcgaacta
gttaactagt aacgcaagtt cacgtaaaaa gggtatcgaa ttcatggctg 120
gttgtaagaa cttcttttgg aagactttca cttcgtgttg atag 164 70 105 DNA
Artificial Sequence synthetic trp promoter 70 aatttgccga catcataacg
gttctggcaa atattctgaa atgagctgtt gacaattaat 60 catcgaacta
gttaactagt acgcaagttc acgtaaaaag ggtat 105 71 308 DNA Homo sapiens
71 atgttctact tcaacaaacc gaccggctat ggctccagct ctcgtcgcgc
accgcagact 60 ggtatcgtag acgagggtgg cgatgaattc atgtgttact
gccaggaccc atatgtaaaa 120 gaagcagaaa accttaagaa atactttaat
gcaggtcatt cagatgtagc ggataatgga 180 actcttttct taggcatttt
gaagaattgg aaagaggaga gtgacagaaa aataatgcag 240 agccaaattg
tctccttcta cttcaagctt gaagttgagc atgaattcgg tatgggcggt 300 gaagctaa
308 72 103 PRT Homo sapiens 72 Met Phe Tyr Phe Asn Lys Pro Thr Gly
Tyr Gly Ser Ser Ser Arg Arg 1 5 10 15 Ala Pro Gln Thr Gly Ile Val
Asp Glu Gly Gly Asp Glu Phe Met Cys 20 25 30 Tyr Cys Gln Asp Pro
Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr 35 40 45 Phe Asn Ala
Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu 50 55 60 Gly
Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Asp Lys Ile Met Gln 65 70
75 80 Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Glu Val Gly His Gly
Phe 85 90 95 Gly Met Gly Gly Glu Ala Lys 100 73 134 DNA Homo
sapiens 73 agcttgaagt tgagcatgaa ttcggtatgg gcggtgaagc taaatctgtg
cgtagatcct 60 cttgctttgg tggccgtatg gaccgcatcg gtgctcagtc
cggtctgggc tgtaactctt 120 tccgttactg atag 134 74 42 PRT Homo
sapiens 74 Lys Leu Glu Val Glu His Glu Phe Gly Met Gly Gly Glu Ala
Lys Ser 1 5 10 15 Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp
Arg Gly Ala Gln 20 25 30 Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 35
40 75 4 PRT Homo sapiens 75 Ser Phe Arg Tyr 1 76 28 PRT Homo
sapiens 76 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg
Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
20 25 77 84 DNA Homo sapiens 77 tctctgcgta gatcctcttg ctttggtggc
cgtatggacc gcatcggtgc tcagtccggt 60 ctggggtgta actctttccg ttac 84
78 111 DNA Artificial Sequence synthetic DNA 78 aatttgccga
catcataacg gttctggcaa atattctgaa atgagctgtt gacaattaat 60
catcgaacta gttaactagt acgcaagttc acgtaaaaag ggtatcgaag g 111 79 167
DNA Artificial Sequence synthetic DNA 79 aatttgccga catcataacg
gttctggcaa atattctgaa atgagctgtt gacaattaat 60 catcgaacta
gttaactagt acgcaagttc acgtaaaaag ggtatcgaat tcatggctgg 120
ttgtaagaac ttcttttgga agactttcac ttcgtgttga taggatc 167 80 107 DNA
Artificial Sequence synthetic DNA 80 aatttgccga catcataacg
gttctggcaa atattctgaa atgagctgtt gacaattaat 60 catcgaacta
gttaactagt acgcaagttc acgtaaaaag ggtatcg 107 81 309 DNA Homo
sapiens CDS (1)..(309) 81 atg ttc tac ttc aac aaa ccg acc ggc tat
ggc tcc agc tct cgt cgc 48 Met Phe Tyr Phe Asn Lys Pro Thr Gly Tyr
Gly Ser Ser Ser Arg Arg 1 5 10 15 gca ccg cag act ggt atc gta gac
gag ggt ggc gat gaa ttc atg tgt 96 Ala Pro Gln Thr Gly Ile Val Asp
Glu Gly Gly Asp Glu Phe Met Cys 20 25 30 tac tgc cag gac cca tat
gta aaa gaa gca gaa aac ctt aag aaa tac 144 Tyr Cys Gln Asp Pro Tyr
Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr 35 40 45 ttt aat gca ggt
cat tca gat gta gcg gat aat gga act ctt ttc tta 192 Phe Asn Ala Gly
His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu 50 55 60 ggc att
ttg aag aat tgg aaa gag gag agt gac aga aaa ata atg cag 240 Gly Ile
Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln 65 70 75 80
agc caa att gtc tcc ttc tac ttc aag ctt gaa gtt gag cat gaa ttc 288
Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Glu Val Glu His Glu Phe 85
90 95 ggt atg ggc ggt gaa gct aaa 309 Gly Met Gly Gly Glu Ala Lys
100 82 103 PRT Homo sapiens 82 Met Phe Tyr Phe Asn Lys Pro Thr Gly
Tyr Gly Ser Ser Ser Arg Arg 1 5 10 15 Ala Pro Gln Thr Gly Ile Val
Asp Glu Gly Gly Asp Glu Phe Met Cys 20 25 30 Tyr Cys Gln Asp Pro
Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr 35 40 45 Phe Asn Ala
Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu 50 55 60 Gly
Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln 65 70
75 80 Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Glu Val Glu His Glu
Phe 85 90 95 Gly Met Gly Gly Glu Ala Lys 100 83 138 DNA Homo
sapiens CDS (3)..(131) 83 ag ctt gaa gtt gag cat gaa ttc ggt atg
ggc ggt gaa gct aaa tct 47 Leu Glu Val Glu His Glu Phe Gly Met Gly
Gly Glu Ala Lys Ser 1 5 10 15 ctg cgt aga tcc tct tgc ttt ggt ggc
cgt atg gac cgc atc ggt gct 95 Leu Arg Arg Ser Ser Cys Phe Gly Gly
Arg Met Asp Arg Ile Gly Ala 20 25 30 cag tcc ggt ctg ggc tgt aac
tct ttc cgt tac tga taggatc 138 Gln Ser Gly Leu Gly Cys Asn Ser Phe
Arg Tyr 35 40 84 42 PRT Homo sapiens 84 Leu Glu Val Glu His Glu Phe
Gly Met Gly Gly Glu Ala Lys Ser Leu 1 5 10 15 Arg Arg Ser Ser Cys
Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln 20 25 30 Ser Gly Leu
Gly Cys Asn Ser Phe Arg Tyr 35 40 85 128 DNA Artificial Sequence
synthetic DNA and Homo sapien hybrid 85 aactagtacg caagttcacg
taaaaagggt atcgataaa atg ttc tac ttc aac 54 Met Phe Tyr Phe Asn 1 5
aaa ccg acc ggc tat ggc tcc agc tct cgt cgc gca ccg cag act ggt 102
Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly 10
15 20 atc gta gac gag ggt ggc gat gaa gg 128 Ile Val Asp Glu Gly
Gly Asp Glu 25 86 29 PRT Artificial Sequence synthetic DNA and Homo
sapien hybrid 86 Met Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser
Ser Ser Arg Arg 1 5 10 15 Ala Pro Gln Thr Gly Ile Val Asp Glu Gly
Gly Asp Glu 20 25 87 393 DNA Homo sapiens CDS (1)..(393) 87 atg ttc
tac ttc aac aaa ccg acc ggc tat ggc tcc agc tct cgt cgc 48 Met Phe
Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg 1 5 10 15
gca ccg cag act ggt atc gta gac gag ggt ggc gat gaa ttc atg tgt 96
Ala Pro Gln Thr Gly Ile Val Asp Glu Gly Gly Asp Glu Phe Met Cys 20
25 30 tac tgc cag gac cca tat gta aaa gaa gca gaa aac ctt aag aaa
tac 144 Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys
Tyr 35 40 45 ttt aat gca ggt cat tca gat gta gcg gat aat gga act
ctt ttc tta 192 Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr
Leu Phe Leu 50 55 60 ggc att ttg aag aat tgg aaa gag gag agt gac
aga aaa ata atg cag 240 Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp
Arg Lys Ile Met Gln 65 70 75 80 agc caa att gtc tcc ttc tac ttc aag
ctt gaa gtt gag cat gaa ttc 288 Ser Gln Ile Val Ser Phe Tyr Phe Lys
Leu Glu Val Glu His Glu Phe 85 90 95 ggt atg ggc ggt gaa gct aaa
tct ctg cgt aga tcc tct tgc ttt ggt 336 Gly Met Gly Gly Glu Ala Lys
Ser Leu Arg Arg Ser Ser Cys Phe Gly 100 105 110 ggc cgt atg gac cgc
atc ggt gct cag tcc ggt ctg ggc tgt aac tct 384 Gly Arg Met Asp Arg
Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser 115 120 125 ttc cgt tac
393 Phe Arg Tyr 130 88 131 PRT Homo sapiens 88 Met Phe Tyr Phe Asn
Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg 1 5 10 15 Ala Pro Gln
Thr Gly Ile Val Asp Glu Gly Gly Asp Glu Phe Met Cys 20 25 30 Tyr
Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr 35 40
45 Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu
50 55 60 Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile
Met Gln 65 70 75 80 Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Glu Val
Glu His Glu Phe 85 90 95 Gly Met Gly Gly Glu Ala Lys Ser Leu Arg
Arg Ser
Ser Cys Phe Gly 100 105 110 Gly Arg Met Asp Arg Ile Gly Ala Gln Ser
Gly Leu Gly Cys Asn Ser 115 120 125 Phe Arg Tyr 130
* * * * *